The American depositary shares of BioNTech SE (BNTX), which made market debut as recently as October 10, 2019, are up an impressive 170 percent based on yesterday's closing price of $44.58.
Germany-based BioNTech is a clinical-stage biotechnology company developing specific immunotherapies for the treatment of cancer and other serious diseases.
The Company has a development pipeline of over 20 product candidates, of which nine have entered into clinical trials. The clinical data updates for up to 5 oncology programs are expected by the end of 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.